CJS Securities Initiates Coverage on Bioventus (NASDAQ:BVS)

Investment analysts at CJS Securities assumed coverage on shares of Bioventus (NASDAQ:BVS) in a report released on Friday, Marketbeat.com reports. The firm set a “market outperform” rating and a $14.00 price target on the stock. CJS Securities’ price target suggests a potential upside of 56.60% from the stock’s current price.

Several other research analysts have also recently commented on BVS. Craig Hallum boosted their target price on Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reissued a “hold (c-)” rating on shares of Bioventus in a research report on Monday, December 29th. Finally, Barrington Research upped their target price on shares of Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, March 6th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $14.00.

Bioventus Price Performance

Shares of BVS opened at $8.94 on Friday. The company has a market cap of $743.36 million, a P/E ratio of 27.09 and a beta of 0.78. Bioventus has a fifty-two week low of $5.81 and a fifty-two week high of $9.56. The company has a quick ratio of 1.19, a current ratio of 1.70 and a debt-to-equity ratio of 1.22. The firm’s 50 day moving average price is $8.49 and its 200 day moving average price is $7.67.

Bioventus (NASDAQ:BVS) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.22 by $0.02. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. The company had revenue of $157.90 million during the quarter. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Insiders Place Their Bets

In other Bioventus news, Director Michelle Mcmurry-Heath sold 12,000 shares of the firm’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total value of $105,480.00. Following the sale, the director directly owned 44,997 shares in the company, valued at $395,523.63. This trade represents a 21.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 33.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd increased its holdings in shares of Bioventus by 17,156.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after acquiring an additional 5,490 shares during the last quarter. PharVision Advisers LLC purchased a new stake in Bioventus during the second quarter worth approximately $67,000. Covestor Ltd lifted its stake in Bioventus by 28.0% during the third quarter. Covestor Ltd now owns 9,951 shares of the company’s stock worth $67,000 after purchasing an additional 2,176 shares during the last quarter. HB Wealth Management LLC acquired a new position in Bioventus in the third quarter valued at approximately $72,000. Finally, Olympiad Research LP purchased a new position in Bioventus in the third quarter valued at approximately $74,000. 62.94% of the stock is owned by institutional investors and hedge funds.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.